Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Galapagos Appoints David Smith as CEO of Service Division

Published: Wednesday, August 21, 2013
Last Updated: Wednesday, August 21, 2013
Bookmark and Share
David Smith was CFO of Galapagos for two years.

Galapagos NV has announced the appointment of David Smith as CEO of the service division and member of the Galapagos Executive Committee.

Galapagos' service division comprises BioFocus and Argenta. Together with Fidelta, Galapagos has three leaders in premium drug discovery services for pharma, biotech, universities, and patient foundations.

Galapagos' service division and Fidelta meet clients' needs for drug discovery tools and expertise by providing a full range of services, from target discovery through to delivery of pre-clinical candidates, including compound libraries, medicinal chemistry and ADME/PK services.

To further optimize the performance and ensure further growth of this division and Fidelta, a CEO position has been created, to be filled by David Smith.

Chris Newton, John Montana and Phil Dudfield will lead BioFocus, Argenta, and Fidelta, respectively, as Managing Director; they will report to David Smith.

David will become member of the Galapagos Executive Committee and report to Galapagos CEO Onno van de Stolpe.

David Smith joins Galapagos from the Cambridge University Hospitals where he was Director Finance for six years. Previously he was CFO of Galapagos for two years, during which he played a key role in several M&A projects to build the service division between 2005 and 2007.

Prior to that, at AstraZeneca he held Marketing Company CFO roles (where he was also a Board member of the AstraZeneca Dutch Holdings Group) and a number of strategic and integration functions within R&D; at Coopers & Lybrand (now PriceWaterhouseCoopers) he was audit manager to a variety of industries and international clients in Dubai, and post qualification as a Chartered Accountant in Leeds he ran a number of companies in administration. David holds a degree in Molecular Biophysics from the University of Leeds.

"We welcome David back to Galapagos," said Onno van de Stolpe, Chief Executive Officer, Galapagos. "David brings valuable strategic and operational experience to the Galapagos Group, and he is already familiar with the services business from his previous role at the Company. We have confidence that he can take the successful Service division to the next level."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Galapagos Starts Phase 1 Study
Company has announced the start of a Phase 1 study with potentiator GLPG2451 for cystic fibrosis (CF).
Tuesday, May 10, 2016
Galapagos Reports Additional Data with Filgotinib
Company has reported 20-week results from its FITZROY study with the investigational, selective JAK1 inhibitor filgotinib in Crohn’s disease.
Saturday, April 23, 2016
Galapagos and MorphoSys initiate Phase 1 study
Company has initiated phase 1 study with MorphoSys AG in joint antibody program MOR106.
Friday, April 08, 2016
Galapagos Starts Saphira Phase 2 Study With Glpg1837 In Cystic Fibrosis Patients
Company has announced its Phase 2 exploratory program of GLPG1837 in patients with cystic fibrosis.
Wednesday, February 17, 2016
Galapagos and Gilead Complete Closing of their Global Collaboration for Filgotinib
Triggers an upfront license fee payment of $300 million and equity investment of $425 million.
Thursday, January 21, 2016
Galapagos Advances CF Clinical Development
Initiation of Phase 1 study with corrector GLPG2222, earning Galapagos a $10 million milestone payment from AbbVie.
Wednesday, January 20, 2016
Galapagos Advances Triple Combination Therapy in Cystic Fibrosis
GLPG2665 enters pre-clinical development and completes the first Galapagos-AbbVie triple combination therapy.
Wednesday, October 21, 2015
Positive Safety and Tolerability for Novel Potentiator GLPG1837
Company presents topline Phase 1 results at the North American Cystic Fibrosis Conference in Phoenix.
Saturday, October 10, 2015
Galapagos Presents Promising Pre-clinical and Phase 1 Results
Company presents results for autotaxin inhibitor GLPG1690 at ERS Annual Meeting.
Saturday, September 26, 2015
Galapagos to Advance Filgotinib to Phase 3 in Rheumatoid Arthritis
Phase 3 start in RA expected in early 2016.
Saturday, September 26, 2015
DARWIN 2 24-week Monotherapy Data in RA Confirm Previous Results
Safety profile in DARWIN 2 consistent with previous filgotinib RA studies.
Tuesday, August 25, 2015
Patient Recruitment Completed in FITZROY Phase 2 Crohn's Disease Study
First selective JAK1 inhibitor in Phase 2 in Crohn's disease.
Friday, August 07, 2015
Galapagos Completes Recruitment for ORIGIN Phase 2 Trial
Recruitment for the Phase 2 Proof-of-Concept study with GPR84 inhibitor GLPG1205 in ulcerative colitis patients.
Saturday, June 20, 2015
Galapagos DARWIN 1 and 2 Studies have Completed 24 Weeks of Treatment
Topline results from final analyses expected to be released in July and August 2015.
Thursday, June 11, 2015
Galapagos Regains Rights to GLPG1690
Filing for Phase 2 clinical trial in 2015.
Thursday, March 19, 2015
Scientific News
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
Treatment of Common Prostate Cancer
Researchers at UTSW have found that the prostate cancer treatments suppress immune response and may promote relapse.
Cancer Drug Could Treat Blood Vessel Deformities
A drug currently being trialled in cancer patients could also be used to treat an often incurable condition that can cause painful blood vessel overgrowths inside the skin.
Structure of Crucial Enzyme Identified
Researchers at UTSW have determined the atomic structure of an enzyme that plays an essential role in cell division and better treatment of cancer.
New Immunotherapy Trial for Type 1 Diabetes
The search for a treatment for Type 1 diabetes (T1D) - which affects over 400,000 people in the UK – will be stepped up with the start of a new phase one clinical trial at Guy’s Hospital in London.
Recruitment of First Patient in Clinical Study
Company has announced recruitment of first patient in clinical study assessing Visco-ease with Beatson Cancer Centre for the treatment of RIX.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!